Edition:
United Kingdom

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.93USD
15 Aug 2018
Change (% chg)

$-0.17 (-2.79%)
Prev Close
$6.10
Open
$6.00
Day's High
$6.00
Day's Low
$5.88
Volume
7,719
Avg. Vol
12,182
52-wk High
$7.76
52-wk Low
$4.75

Chart for

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 2.53
Market Cap(Mil.): $568.33
Shares Outstanding(Mil.): 94.09
Dividend: --
Yield (%): --

Financials

  MESO.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.00 -- --
ROI: -12.06 1.78 14.61
ROE: -14.70 3.28 16.33

BRIEF-Mesoblast ‍Enters $75 Mln Non-Dilutive Credit Facility

* ENTERED US$75 MILLION NON-DILUTIVE, FOUR-YEAR CREDIT FACILITY WITH HERCULES CAPITAL

07 Mar 2018

BRIEF-Mesoblast Posts ‍Qtrly Profit Attributable Of $13.7 Mln

* ‍QTRLY PROFIT ATTRIBUTABLE $13.7 MILLION VERSUS LOSS OF $20.1 MILLION ​ Source text for Eikon: Further company coverage:

27 Feb 2018

BRIEF-Mesoblast Says ‍Primary Endpoint Achieved In A Phase 3 Cell Therapy Trial

* ‍PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST'S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

22 Feb 2018

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study

Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

21 Feb 2018

Mesoblast stem cell therapy meets goal of pediatric Graft vs Host study

Feb 21 Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

21 Feb 2018

Earnings vs. Estimates